The Risk of Pulmonary Embolism and Deep Vein Thrombosis in Major Rheumatic Diseases

Project number: 
13-031
Approval date: 
Tuesday, March 25, 2014
Principal Investigator: 
Avina-Zubieta,Antonio
Institution: 
Arthritis Research Centre of Canada
Funding Agency: 
Canadian Institutes of Health Research(CIHR)
Datasets requested: 
Income band (Statistics Canada)
PharmaCare (BC Ministry of Health)
consolidation - census geocodes
PharmaNet
bc cancer
Medical Services Plan (BC Ministry of Health)
Consolidation - demographic (Ministry of Health)
Perinatal Services BC
Deaths (BC Vital Statistics Agency)
Hospital Separations (BC Ministry of Health)
Consolidation registry (Ministry of Health)
Research objective: 

1. To evaluate the risk of pulmonary embolism (PE) and deep vein thrombosis (DVT) in major rheumatic diseases, including rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), gout, systemic autoimmune rheumatic diseases (SARDs) and osteoarthritis (OA).

2. To evaluate potential anti-thrombotic benefits of anti-rheumatic drugs in major rheumatic diseases.

HYPOTHESES

1. Each major rheumatic disease is independently associated with an increased risk of PE and DVT.

2. Use of anti-rheumatic therapy may reduce the risk of VTE in affected individuals.

The proposed population-based study will be a timely, comprehensive evaluation of risk for PE and DVT among prototypic rheumatic conditions in general population contexts. This studys large-scale yet cost-efficient approach will provide the relevant data on this critical outcome, filling major gaps in our endeavour to improve the overall outcomes in those living with lifelong inflammatory arthritic conditions.


Page last revised: December 5, 2017